Cannabis gel trialled in epilepsy

Melbourne neurologists are leading the first randomised controlled trial into the transdermal application of cannabidiol (CBD) gel in adult patients with partial onset seizures.

The Phase 2 trial will randomise patients to either CBD 195mg every 12 hours, CBD 97.5mg every 12 hours or placebo gel every 12 hours for 12 weeks before moving to an open-label phase.

The gel will be applied to the skin of both right and left shoulder or